Breaking Finance News

A statement released earlier today by RBC Capital about Seattle Genetics (NASDAQ:SGEN) raises the target price to $58.00

Seattle Genetics (NASDAQ:SGEN) had its target price raised to $58.00 by RBC Capital in a report released 09/15/2017. The new target price indicates a possible upside of 0.09% based on the company's last stock close price.

Yesterday Seattle Genetics (NASDAQ:SGEN) traded 1.05% higher at $53.15. The company’s 50-day moving average is $49.60 and its 200-day moving average is $59.25. The last stock close price is down -9.37% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 124,489 shares of the stock were exchanged, down from an average trading volume of 1,250,890

See Chart Below

Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics has a 52 week low of $45.31 and a 52 week high of $75.36 The company’s market cap is currently $0.

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.